Calithera Biosciences, Inc. (CALA) Financial Statements (2024 and earlier)

Company Profile

Business Address 343 OYSTER POINT BLVD #200
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:59,537107,14660,43751,058163,79351,800
Cash and cash equivalents59,537107,14660,43751,05848,47510,601
Short-term investments     115,31841,180
Other undisclosed cash, cash equivalents, and short-term investments      19
Receivables  1,5414821,9971,142 
Other undisclosed current assets1,91510,01698,87787,1972,7321,761
Total current assets:61,452118,703159,796140,252167,66753,561
Noncurrent Assets
Operating lease, right-of-use asset2,4785,754 
Property, plant and equipment5566909921,4641,759899
Long-term investments and receivables     22,361 
Long-term investments     22,361 
Restricted cash and investments27044044044044046
Other noncurrent assets   280569228290
Other undisclosed noncurrent assets   7,260   
Total noncurrent assets:3,3046,8848,9722,47324,7881,235
TOTAL ASSETS:64,756125,587168,768142,725192,45554,796
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,5468,58819,62414,88110,0104,453
Employee-related liabilities3,2835,142    
Accounts payable3,6501,9942,0521,2471,072398
Accrued liabilities6131,45217,57213,6348,9384,055
Deferred revenue and credits29,017 
Other undisclosed current liabilities6,4609,813    
Total current liabilities:14,00618,40119,62414,88139,0274,453
Noncurrent Liabilities
Long-term debt and lease obligation: 1,6664,815    
Liabilities, other than long-term debt   1,1303,121437
Deferred revenue and credits3,121437
Deferred rent credit    1,130
Operating lease, liability1,6664,815 
Other undisclosed noncurrent liabilities(1,666)(4,815)6,718   
Total noncurrent liabilities:1,6664,8156,7181,1303,121437
Total liabilities:15,67223,21626,34216,01142,1484,890
Temporary equity, carrying amount 40,702     
Equity
Equity, attributable to parent8,382102,371142,426126,714150,30749,906
Preferred stock      
Common stock 876442
Additional paid in capital499,700478,599428,479322,993300,906172,419
Accumulated other comprehensive income (loss)  342(113)(270)(13)
Accumulated deficit(491,326)(376,238)(286,101)(196,170)(150,333)(122,502)
Total equity:8,382102,371142,426126,714150,30749,906
TOTAL LIABILITIES AND EQUITY:64,756125,587168,768142,725192,45554,796

Income Statement (P&L) ($ in thousands)

12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues 9,750187 22,25425,955 
Revenue, net25,955 
Sublease income  187 
Gross profit: 9,750187 22,25425,955 
Operating expenses(125,183)(91,387)(92,895)(79,535)(55,641)(38,334)
Other undisclosed operating loss  (187)    
Operating loss:(115,433)(91,387)(92,895)(57,281)(29,686)(38,334)
Nonoperating income (expense)(2)142897272(446) 
Investment income, nonoperating (2)142897272(446) 
Other nonoperating income      
Other undisclosed income from continuing operations before equity method investments, income taxes  1,1082,1382,3802,306 
Loss from continuing operations before equity method investments, income taxes:(115,435)(90,137)(89,860)(54,629)(27,826)(38,334)
Other undisclosed income from continuing operations before income taxes 347     
Loss from continuing operations:(115,088)(90,137)(89,860)(54,629)(27,826)(38,334)
Loss before gain (loss) on sale of properties:(115,088)(90,137)(89,860)(54,629)(27,826)(38,334)
Net loss:(115,088)(90,137)(89,860)(54,629)(27,826)(38,334)
Other undisclosed net income attributable to parent      330
Net loss attributable to parent:(115,088)(90,137)(89,860)(54,629)(27,826)(38,004)
Other undisclosed net income available to common stockholders, basic      
Net loss available to common stockholders, basic:(115,088)(90,137)(89,860)(54,629)(27,826)(38,004)
Dilutive securities, effect on basic earnings per share      
Net loss available to common stockholders, diluted:(115,088)(90,137)(89,860)(54,629)(27,826)(38,004)

Comprehensive Income ($ in thousands)

12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(115,088)(90,137)(89,860)(54,629)(27,826)(38,334)
Comprehensive loss:(115,088)(90,137)(89,860)(54,629)(27,826)(38,334)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (3)(39)155157(257)386
Comprehensive loss, net of tax, attributable to parent:(115,091)(90,176)(89,705)(54,472)(28,083)(37,948)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: